Navigation Links
Third Pivotal Phase 3 Study for NicOx' Naproxcinod Shows Positive Efficacy, Safety and Blood Pressure Results
Date:11/24/2008

on (CRO).

NOTE: Office Blood Pressure Measurements (OBPMs) were performed by a health care professional during a patient's visit to the treatment center using a standard technique and equipment (i.e. a sphygmomanometer). OBPMs were performed in the morning and the time between intake of study-drug and measurement of OBPM was between 2 and 4 hours.

NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is a product-driven biopharmaceutical company dedicated to the development and future commercialization of investigational drugs for unmet medical needs. NicOx is applying its proprietary nitric oxide-donating technology to develop an internal portfolio of New Chemical Entities (NCEs) in the therapeutic areas of inflammatory and cardio-metabolic disease.

Resources are focused on the development and pre-commercialization activities for naproxcinod, a proprietary NCE and the first compound in the Cyclooxygenase-Inhibiting Nitric Oxide-Donating (CINOD) class of anti-inflammatory agents for the treatment of the signs and symptoms of osteoarthritis. Naproxcinod has completed three pivotal phase 3 studies with positive results and the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) is projected for mid-2009.

Beyond naproxcinod, NicOx has a pipeline containing multiple nitric oxide-donating NCEs, which are in development internally and with partners, including Pfizer Inc and Merck & Co., Inc., for the treatment of prevalent and underserved diseases, such as atherosclerosis, hypertension, widespread eye diseases and Chronic Obstructive Pulmonary Disease (COPD).

NicOx S.A. is headquartered in France and is listed on the NYSE Euronext Paris (Compartment B: Mid Caps).

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statemen
'/>"/>

SOURCE NicOx
Copyright©2008 PR Newswire.
All rights reserved

13611

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Over $10 Million of CSL Behrings Privigen Was Sold in the U.S. During the Third Quarter of 2008
2. SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results
3. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
4. CuraGen to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results and CR011-vcMMAE Phase II Trial Results on November 3, 2008
5. Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent
6. Physicians Estimate That if Approved, Ceftobiprole Will Steal Nearly a Third of Zyvoxs Patient Share in the Treatment of Nosocomial Pneumonia
7. NewCardio Announces Positive Results From Third Clinical Validation Study
8. Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008
9. NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study
10. NeoStem Reports Positive Stem Cell Industry Research Trends From The Journal of the American Medical Association and Third Annual Stem Cell Summit
11. Tengion Launches Third Phase 2 Clinical Trial of Regenerated Human Bladder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Sept. 30, 2014  Based on its recent ... & Sullivan recognizes Ventana Medical Systems, Inc. (Ventana), ... 2014 North American Frost & Sullivan Award for ... along with a focus on innovation and improving ... in tissue-based cancer diagnostic solutions for patients worldwide. ...
(Date:9/30/2014)... September 30, 2014 The report ... Market Size, Share, Growth and Forecast, 2007 - 2017," ... worth USD 20.8 billion in 2012 and is further ... at a CAGR of 7.3% from 2012 to 2017. ... various health purposes, especially to prevent chronic diseases that ...
(Date:9/30/2014)... 30. September 2014 ... Acutus Medical, ... minimal-invasives 3D-Herzkammer-Bildgebungs- und Dipoldichte-Mappingsystem in Echtzeit ... zu komplexen Herzrhythmusstörungen einschließlich Vorhofflimmern führen ... einer zusätzlichen Finanzierung über 26,2 Mio. ...
Breaking Medicine Technology:Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 3Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 4Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 2Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 3Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 4Acutus Medical, Inc. schließt zusätzliche Finanzierungsrunde Serie B über 26,2 Mio. USD ab, um Portfolio-Erweiterung zu finanzieren 2Acutus Medical, Inc. schließt zusätzliche Finanzierungsrunde Serie B über 26,2 Mio. USD ab, um Portfolio-Erweiterung zu finanzieren 3
... to dramatically reduce the risk of cancer ... EAST HANOVER, N.J., April 12, 2007 /PRNewswire/ ... tablets to,patients receiving placebo in a major ... showed participants with Kit-positive,gastrointestinal stromal tumors treated ...
... 2007 - Immunicon,Corporation (NASDAQ-GM:IMMC) will exhibit at ... the Los Angeles,Convention Center, April 15 to ... the new CellCapture(TM) CTC,Mouse/Rat Kit and the ... Pharma Services offers assay development and clinical,trial ...
Cached Medicine Technology:Positive Results Prompt US National Cancer Institute to Make,Gleevec Available To Patients in Post-Surgical Gist Study 2Positive Results Prompt US National Cancer Institute to Make,Gleevec Available To Patients in Post-Surgical Gist Study 3Positive Results Prompt US National Cancer Institute to Make,Gleevec Available To Patients in Post-Surgical Gist Study 4Positive Results Prompt US National Cancer Institute to Make,Gleevec Available To Patients in Post-Surgical Gist Study 5Positive Results Prompt US National Cancer Institute to Make,Gleevec Available To Patients in Post-Surgical Gist Study 6Positive Results Prompt US National Cancer Institute to Make,Gleevec Available To Patients in Post-Surgical Gist Study 7Immunicon Will Exhibit CellCapture CTC Mouse/Rat Kit and EasyCount,System for Automated Cell Counting at AACR 2Immunicon Will Exhibit CellCapture CTC Mouse/Rat Kit and EasyCount,System for Automated Cell Counting at AACR 3Immunicon Will Exhibit CellCapture CTC Mouse/Rat Kit and EasyCount,System for Automated Cell Counting at AACR 4
(Date:9/30/2014)... 2014 Research by UC Irvine immunologists reveals new ... on a vital process that determines how the body,s ... version of Nature Immunology , neurology professor Dr. ... for Immunology colleagues describe a critical mechanism underlying how ... bloodstream. , A T cell is a type of ...
(Date:9/30/2014)... NV (PRWEB) September 30, 2014 EverStryke ... a free introduction to SurvivalLife.com along with a free book ... the attention of Shane Michaels, prompting an investigative review. ... well-known people in the survival and preparation niche, and this ... of the great classes and survival products that Joe offers ...
(Date:9/30/2014)... 30, 2014 VisitandCare.com reports ... has gone up more than 79 percent in 2014, ... company also reported total revenue tripled for its entirety ... company’s professional strategy has allowed them to partner with ... for patient comfort and privacy — with state-of-the-art surgical ...
(Date:9/30/2014)... Regenerative Medicine Solutions (RMS) is set ... Nashville, Tennessee. RMS welcomes the launch of an entirely ... of a new treatment center for the Lung Institute. ... Institute to Nashville, the hope is to bring awareness ... diagnosed and undiagnosed. With Nashville being a hub for ...
(Date:9/30/2014)... 30, 2014 Bifidobacteria, the primary bacteria ... poor diet, and stress, so a high Bifido probiotic ... of Ultimate Flora™ Men’s Complete contains 90 ... 7 Bifidobacteria strains to support a healthy large intestine ... up, and 32 billion cultures from 7 Lactobacillus strains ...
Breaking Medicine News(10 mins):Health News:UCI study uncovers important process for immune system development 2Health News:EverStryke: Review Exposes Joe Marshall’s Permanent Match Survival Product 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 3Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 4Health News:Regenerative Medicine Solutions Expanding 2Health News:ReNew Life Introduces Ultimate Flora™ Men’s Complete Probiotic 90 Billion—Comprehensive Probiotic Support Just for Men 2
... Institutes of Health in the United States has evaluated the ... and the average quantity of alcohol drunk per occasion and ... well as all cancers. The analysis is based on ... US, assessing more than 300,000 subjects who suffered over 8,000 ...
... age, forgetfulness and other signs of memory loss sometimes appear, ... that they may be experiencing early symptoms of Alzheimer,s disease ... 65 and older. But even when early memory problems ... variable. Some patients are at high risk while others are ...
... HealthDay Reporter , WEDNESDAY, Oct. 19 (HealthDay News) ... a lumpectomy have significantly fewer recurrences and, consequently, greater ... research says. The study also noted no ... as deaths from any cause were also reduced substantially. ...
... recent UT Southwestern Medical Center study found that estrogen regulates ... in specific parts of the brain may lead to obesity. ... Deborah Clegg, associate professor of internal medicine and senior author ... . "We hadn,t previously thought of sex hormones as being ...
... HealthDay Reporter , WEDNESDAY, Oct. 19 (HealthDay News) ... after birth interferes with development of the brain,s cerebellum, ... new research finds. For the study, researchers analyzed ... weeks, gestation) at two medical centers, the University of ...
... Department of Defense (DoD) Congressionally Directed Medical Research ... has awarded a $19.7 million grant to the ... consortium that will improve the quality of life ... combat. The Bridging Advanced Developments for ...
Cached Medicine News:Health News:Association of quantity of alcohol and frequency of consumption with cancer mortality 2Health News:Combination of available tests helps predict Alzheimer's disease risk 2Health News:Breast Radiation After Lumpectomy Saves Lives: Study 2Health News:UT Southwestern study shows estrogen works in the brain to keep weight in check 2Health News:Steroids Given to Preemies May Harm Brain Growth: Study 2Health News:Steroids Given to Preemies May Harm Brain Growth: Study 3Health News:University of Delaware to lead DoD orthopaedic rehabilitation consortium 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: